International journal of clinical oncology
-
Int. J. Clin. Oncol. · Oct 2009
Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer.
Recently, randomized trials revealed that trastuzumab as adjuvant treatment was effective in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients. Safety information on adjuvant trastuzumab use in Japanese patients, especially cardiac toxicity data, is needed. ⋯ The incidence of cardiac events caused by trastuzumab treatment was low in our analysis. Adjuvant trastuzumab treatment for up to at least 1 year should be safe for Japanese breast cancer patients.